Summary of COVID-19 plasma-activated water studies

1. Zhao et al., Nebulized inhalation of plasma-activated water in the treatment of progressive moderate COVID-19 patients with antiviral treatment failure: a randomized controlled pilot trial

23 patient plasma-activated water late treatment RCT: 9% higher progression (p=1), 73% greater improvement (p=0.04), 28% shorter hospitalization (p=0.16), and 30% higher hospital discharge (p=0.24).
RCT 23 moderate COVID-19 patients with antiviral treatment failure, showing nebulized plasma-activated water (PAW) improved chest CT and accelerated cough resolution compared to saline control, however there was no significant difference in progression. No adverse reactions were reported. Authors suggest that PAW may disrupt SARS-CoV-2 binding and replication and have anti-inflammatory effects in the lungs.
Sep 2024, BMC Infectious Diseases, https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-024-09886-w, https://c19p.org/zhao14